Background. Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods. In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margins and a low number of lymph nodes harvested), as well as tumor histologic subtype, were associated with cancer-specific survival in 66 stage II non-ampullary small bowel adenocarcinoma patients, collected through the Small Bowel Cancer Italian Consortium. A central histopathology review was performed. Mismatch repair deficiency was tested by immunohistochemistry for MLH1, MSH2, MSH6 and PMS2, and confirmed by polymerase chain reaction for microsatellite instability. Results. We identified mismatch repair deficiency, glandular/medullary histologic subtype, and celiac disease as significant predictors of favorable cancer-specific survival using univariable analysis with retained significance in bivariable models adjusted for pT stage. Among the high-risk features, only T4 showed a significant association with an increased risk of death; however, its prognostic value was not independent of mismatch repair status. Conclusions. Mismatch repair protein expression, histologic subtype, association with celiac disease, and, in the mismatch repair proficient subset only, T stage, may help identify patients who may benefit from adjuvant chemotherapy.

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas / A. Vanoli, F. Grillo, C. Guerini, G. Neri, G. Arpa, C. Klersy, G. Nesi, P. Giuffrida, G. Sampietro, S. Ardizzone, P. Fociani, R. Fiocca, G. Latella, F. Sessa, A. D'Errico, D. Malvi, C. Mescoli, M. Rugge, S. Ferrero, G. Poggioli, F. Rizzello, M.C. Macciomei, D. Santini, U. Volta, R. De Giorgio, G. Caio, A. Calabrò, C. Ciacci, M. D'Armiento, A. Rizzo, G. Solina, M. Martino, F. Tonelli, V. Villanacci, R. Cannizzaro, V. Canzonieri, A.M. Florena, L. Biancone, G. Monteleone, R. Caronna, A. Ciardi, L. Elli, F. Caprioli, M. Vecchi, R. D'Incà, F. Zingone, A. D'Odorico, M.V. Lenti, B. Oreggia, L. Reggiani Bonetti, A.G. Giannone, A. Orlandi, V. Barresi, R. Ciccocioppo, G. Amodeo, E. Biletta, O. Luinetti, P. Pedrazzoli, A. Pietrabissa, G.R. Corazza, E. Solcia, M. Paulli, A. Di Sabatino. - In: ANNALS OF SURGICAL ONCOLOGY. - ISSN 1068-9265. - 28:2(2021 Feb), pp. 1167-1177. [10.1245/s10434-020-08926-4]

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

S. Ardizzone;S. Ferrero;L. Elli;F. Caprioli;M. Vecchi;
2021

Abstract

Background. Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods. In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margins and a low number of lymph nodes harvested), as well as tumor histologic subtype, were associated with cancer-specific survival in 66 stage II non-ampullary small bowel adenocarcinoma patients, collected through the Small Bowel Cancer Italian Consortium. A central histopathology review was performed. Mismatch repair deficiency was tested by immunohistochemistry for MLH1, MSH2, MSH6 and PMS2, and confirmed by polymerase chain reaction for microsatellite instability. Results. We identified mismatch repair deficiency, glandular/medullary histologic subtype, and celiac disease as significant predictors of favorable cancer-specific survival using univariable analysis with retained significance in bivariable models adjusted for pT stage. Among the high-risk features, only T4 showed a significant association with an increased risk of death; however, its prognostic value was not independent of mismatch repair status. Conclusions. Mismatch repair protein expression, histologic subtype, association with celiac disease, and, in the mismatch repair proficient subset only, T stage, may help identify patients who may benefit from adjuvant chemotherapy.
Settore MED/12 - Gastroenterologia
feb-2021
5-ago-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Prognostic-Role-of-Mismatch-Repair-Status-Histotype-and-HighRisk-Pathologic-Features-in-Stage-II-Small-Bowel-Adenocarcinomas2020Annals-of-Surgical-Oncology.pdf

accesso aperto

Descrizione: Online first
Tipologia: Publisher's version/PDF
Dimensione 1.18 MB
Formato Adobe PDF
1.18 MB Adobe PDF Visualizza/Apri
Vanoli2021_Article_PrognosticRoleOfMismatchRepair.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.17 MB
Formato Adobe PDF
1.17 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/801157
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
social impact